All In Biotech

NDA 208036 · Bracco

E-Z-Cat Dry

Barium Sulfate · Oral · Radiographic Contrast Agent

Last checked: Nov 20, 2026Latest source record: Apr 30, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jan 11, 2016

Approved uses

4

Original approval plus efficacy supplements

Registered trials

25

4 Phase 3, 5 recruiting

FAERS reports

351

260 serious, 31 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

VARIBAR THIN LIQUID is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR THIN LIQUID is a radiopaque contrast agent indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • E-Z-CAT DRY · BARIUM SULFATE 40% · FOR SUSPENSION, ORAL · Discontinued
  • E-Z-HD · BARIUM SULFATE 98% · FOR SUSPENSION, ORAL · Prescription
  • VARIBAR THIN LIQUID · BARIUM SULFATE 81% · FOR SUSPENSION, ORAL · Prescription
  • E-Z-PAQUE · BARIUM SULFATE 96% · FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Barium" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • aspiration68
  • no adverse event25
  • renal failure18
  • acute kidney injury17
  • urticaria16
  • chronic kidney disease15
  • diarrhoea15
  • dyspnoea15
  • rash14
  • cough13
  • pruritus13
  • vomiting13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20073
20088
20094
20108
201114
201212
201318
201412
20159
201624
201727
201818
201921
202019
202175
202220
202318
202410
202519
20267

Recalls

2 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Jul 2, 2014 · Class III · Terminated

    Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 728 on PubMed

Sponsor: Bracco · Also marketed as E-Z-Hd, Varibar Thin Liquid, E-Z-Paque

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.